Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial
- 27 March 2009
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 24 (3) , 233-238
Abstract
Objective: Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, particularly in negative symptoms. This study investigates the efficacy of adding mirtazapine to treatment as usual to alleviate the negative symptoms of schizophrenia.Methods: In a 6 week, double‐blind clinical trial, participants with a diagnosis of schizophrenia and currently being treated with atypical antipsychotic medication were randomised to adjunctive treatment with mirtazapine (30 mg/day) or placebo. The primary outcome measure was improvement in the Positive and Negative Syndrome Scale (PANSS). Measures of cognition, collected at baseline and week 6 only, were analysed using an Analysis of Covariance (ANCOVA) model. All other outcome measures were analysed using a linear mixed model.Results: Forty participants were recruited to the study with equal numbers randomised to each treatment arm. There was no significant difference between mirtazapine and placebo treated participants for improvement in PANSS scores or any of the secondary outcome measures at any stage during the 6‐week trial.Conclusions: This trial does not confirm previous research supporting the use of mirtazapine adjunctive to atypical antipsychotic treatment for schizophrenia. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled TrialBiological Psychiatry, 2008
- Inverse Agonist and Neutral Antagonist Actions of Antidepressants at Recombinant and Native 5-Hydroxytryptamine2C Receptors: Differential Modulation of Cell Surface Expression and Signal TransductionMolecular Pharmacology, 2008
- The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled studySchizophrenia Research, 2007
- Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of SchizophreniaThe Journal of Clinical Psychiatry, 2007
- The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled studyInternational Clinical Psychopharmacology, 2004
- Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled studyEuropean Neuropsychopharmacology, 2003
- Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double‐blind randomised parallel group placebo‐controlled trialHuman Psychopharmacology: Clinical and Experimental, 2003
- Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesiaInternational Clinical Psychopharmacology, 1997
- Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant SchizophreniaThe British Journal of Psychiatry, 1996
- Biochemical Findings of Negative Symptoms in Schizophrenia and Their Putative Relevance to Pharmacological TreatmentNeuropsychobiology, 1994